Want to see GDRX full AI Analyst Report?
Top Page
GoodRx Holdings
(NASDAQ:GDRX)
Select Model
Select Model
Rating:67Neutral
Price Target:
$3.50
▲(18.24% Upside)
Action:Downgraded
Date:06/19/26
The score is primarily supported by improved financial quality (profitability, strong gross margins, positive free cash flow, and sharply lower leverage) and a constructive earnings update with raised 2026 guidance driven by strong Pharma Direct momentum. Offsetting this are weak top-line trends in the legacy business, a relatively high P/E with no dividend support, and mixed technical signals that do not confirm a sustained uptrend.
Positive Factors
Stronger Balance Sheet
Debt-to-equity collapsing from ~0.75–0.93 to ~0.09–0.10 materially reduces financial risk and increases strategic optionality. Lower leverage supports capital allocation for growth, M&A, or buybacks and improves resilience to cyclical shocks while equity and positive ROE (~4.8% TTM) underpin stability.
Negative Factors
Declining Legacy Prescription Transactions
A 24% YoY decline in core prescription transactions erodes the historical revenue base and higher-margin flows. Persistent PTR weakness requires the company to replace substantial legacy volume with newer initiatives; failure to fully offset this structural decline risks sustained top-line pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger Balance Sheet
Debt-to-equity collapsing from ~0.75–0.93 to ~0.09–0.10 materially reduces financial risk and increases strategic optionality. Lower leverage supports capital allocation for growth, M&A, or buybacks and improves resilience to cyclical shocks while equity and positive ROE (~4.8% TTM) underpin stability.
Read all positive factors
GoodRx Holdings Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down earnings by different business areas, revealing which segments drive growth and where the company might face challenges or opportunities.
Breaks down earnings by different business areas, revealing which segments drive growth and where the company might face challenges or opportunities.
Data provided by:
The Fly
The FlyGoodRx Holdings (GDRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.04B
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)52.4
Beta (1Y)0.92
Revenue Growth-1.19%
EPS Growth-21.87%
CountryUS
Employees697
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.06
Shares Outstanding104,711,190
10 Day Avg. Volume911,183
30 Day Avg. Volume1,022,773
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.60Price Target Upside21.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.31
Revenue Forecast (FY)$775.87M
GoodRx Holdings Business Overview & Revenue Model
Company Description
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering cust...
How the Company Makes Money
GoodRx primarily makes money by monetizing prescription transactions and related healthcare services facilitated through its platform. A major revenue stream is prescription-related revenue tied to its discount programs: when a consumer uses a Goo...
GoodRx Holdings Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call balanced material near-term headwinds in the legacy prescription transactions business (PTR) — notably a 24% YoY decline in PTR revenue and persistent unit-economics pressure — against strong and accelerating growth in strategic areas (Pharma Direct up 82% YoY, subscriptions +16% YoY), improved operational scalability in e-commerce, and a raised full-year guidance. Management emphasized durable strategy execution, margin discipline (30% adjusted EBITDA margin in Q1), and momentum in Pharma Direct and condition-specific subscriptions. While legacy PTR trends and macro/regulatory uncertainty are notable risks, the company’s improved guidance, profitable quarter, and rapid Pharma Direct expansion weigh positively.Positive Updates
Q1 Revenue and Profitability
Reported revenue of $194 million in Q1 2026 and adjusted EBITDA of $58.3 million, representing a 30% adjusted EBITDA margin.
Negative Updates
Decline in Prescription Transactions Revenue (PTR)
Prescription transactions revenue was $113.7 million in Q1, down 24% year-over-year, driven by lapping impacts from 2025 and unit economics pressure in the legacy PTR business.
Read all updates
Q1-2026 Updates
Positive
Negative
Q1 Revenue and Profitability
Reported revenue of $194 million in Q1 2026 and adjusted EBITDA of $58.3 million, representing a 30% adjusted EBITDA margin.
Read all positive updates
Company Guidance
GoodRx raised full-year 2026 guidance, now expecting revenue of $765–$785 million and adjusted EBITDA of at least $235 million, driven primarily by stronger-than-expected Pharma Direct performance; in Q1 the company reported revenue of $194 million, adjusted EBITDA of $58.3 million (30% margin), prescription transactions revenue of $113.7 million (down 24% YoY) with monthly active consumers roughly flat sequentially at 5.3 million, Pharma Direct revenue of $52.2 million (up 82% YoY and now expected to grow >50% YoY for 2026), subscription revenue of $24.4 million (up 16% YoY) as subscription plans returned to YoY growth, over 125 self-pay programs live, e-commerce order volume and claims more than doubled quarter-over-quarter, and direct contracts in place with 9 of the top 10 retail pharmacies.GoodRx Holdings Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 787.89M | 796.85M | 792.32M | 750.26M | 766.55M | 745.42M |
| Gross Profit | 681.98M | 739.26M | 744.11M | 683.34M | 701.48M | 698.71M |
| EBITDA | 173.34M | 184.36M | 153.92M | 108.82M | 65.19M | 48.00M |
| Net Income | 20.56M | 30.44M | 16.39M | -8.87M | -32.83M | -25.25M |
Balance Sheet | ||||||
| Total Assets | 2.02B | 1.40B | 1.39B | 1.59B | 1.60B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 235.71M | 261.82M | 448.35M | 672.30M | 757.16M | 941.11M |
| Total Debt | 541.35M | 542.81M | 543.39M | 711.07M | 717.02M | 702.33M |
| Total Liabilities | 1.40B | 787.80M | 663.41M | 826.84M | 789.80M | 775.95M |
| Stockholders Equity | 621.99M | 616.26M | 724.66M | 761.96M | 814.83M | 831.68M |
Cash Flow | ||||||
| Free Cash Flow | 96.54M | 164.38M | 113.55M | 82.53M | 91.57M | 144.32M |
| Operating Cash Flow | 170.33M | 167.90M | 183.89M | 138.29M | 146.78M | 178.78M |
| Investing Cash Flow | -89.73M | -119.96M | -70.35M | -55.77M | -210.50M | -178.73M |
| Financing Cash Flow | -145.87M | -234.47M | -337.50M | -167.40M | -120.23M | -30.53M |
GoodRx Holdings Technical Analysis
Positive
2.96
Price Trends
2.90
Positive
2.60
Positive
2.68
Positive
Market Momentum
0.09
Negative
65.44
Neutral
69.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Positive. The current price of 2.96 is below the 20-day moving average (MA) of 3.06, above the 50-day MA of 2.90, and above the 200-day MA of 2.68, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 65.44 is Neutral, neither overbought nor oversold. The STOCH value of 69.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GDRX.
GoodRx Holdings Risk Analysis
GoodRx Holdings disclosed 2 risk factors in its most recent earnings report. GoodRx Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GoodRx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.18B | -172.97 | -2.81% | ― | 49.36% | 83.76% | |
69 Neutral | $103.68M | 30.65 | 16.87% | ― | 10.34% | ― | |
67 Neutral | $1.04B | 52.39 | 3.31% | ― | -1.19% | -21.87% | |
66 Neutral | $663.24M | 70.50 | 2.79% | ― | 14.05% | ― | |
55 Neutral | $179.62M | -1.98 | -33.27% | ― | -9.29% | 46.89% | |
52 Neutral | $1.22B | -6.78 | -13.08% | ― | -2.08% | 16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GDRX
GoodRx Holdings
3.27
-1.07
-24.65%
CCLD
CareCloud
2.54
>-0.01
-0.39%
TDOC
Teladoc
6.93
-0.06
-0.86%
PHR
Phreesia
11.49
-15.62
-57.62%
AMWL
American Well
13.02
5.16
65.65%
OMDA
Omada Health, Inc.
19.11
-0.33
-1.70%
GoodRx Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
GoodRx Stockholders Approve Directors, Auditor and Executive Pay
Positive
Jun 18, 2026
On June 16, 2026, GoodRx Holdings, Inc. held its annual meeting of stockholders, with holders of its dual-class shares representing about 99.4% of total voting power present in person or by proxy as of the April 20, 2026 record date. Stockholders ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.